Life Sciences Law & Industry Report connects the dots among the many disciplines that make up the burgeoning life sciences industry, with biweekly updates on current regulatory, legislative,...
Nov. 15 — The PTO's inter partes review process to invalidate existing patents continues to rattle biopharma patent owners, conference panelists said Nov. 15.
The number of IPR petitions is growing, and method and composition claims are the most likely to be found unpatentable by the Patent and Trademark Office’s Patent Trial and Appeal Board, said Robert F. Shaffer, an attorney with Finnegan, Henderson, Farabow, Garrett & Dunner LLP in Washington, based on the law firm’s analysis of PTO data.
But James Harrington, senior vice president and chief intellectual property counsel for Dublin-based Shire Pharmaceuticals, said the problem isn't with the IPR process but with the PTO’s initial review of the patents.
He cited Finnegan’s research, saying, “63 percent of the IPR petitions for which trials are instituted are for biopharma claims. It should be 5 or 6 percent. The PTO needs to be getting it right. We need to have certainty in our patents. When they come out, they should be right.”
The session, titled “Five Years of Living with the AIA: The Impact of IPR on Pharmaceutical Patents,” was part of the BIO IP Counsels Committee Conference in Savannah, Ga.
The IPR process was created by the America Invents Act to allow third-party challenges to the validity of issued patents on the grounds that the claims were anticipated or rendered obvious by prior patents or publications. It was designed to be a faster and less expensive method of challenging patents than federal district court litigation.
Nicole A. Conlon, a Finnegan associate attorney, said the firm’s analysis shows the process is achieving the PTAB’s goals for speed. But she noted that 83 percent of IPRs have parallel proceedings ongoing in federal district court. Harrington said this “only points out that the IPR process isn’t cheap after all.”
The Biotechnology Innovation Organization in Washington, which sponsored the conference, has said the IPR process is being misused by hedge fund companies whose motive isn't to develop their own products but to make money by selling company stocks short.
The Coalition for Affordable Drugs (CAD), which was created by hedge fund manager Kyle Bass, has filed three dozen IPR petitions against biopharma patents.
The CAD has challenged the validity of several Shire patents through the IPR process. On Oct. 21, 2015, the PTAB found most of the claims of Shire’s patent on Gattex (teduglutide), a treatment for short bowel syndrome, invalid. But on Oct. 5, 2016, the PTAB upheld the validity of Shire’s only patent on its colitis drug Lialda (mesalamine) against a CAD IPR challenge.
“If the IPR institution rate for biopharmas were lower, Kyle Bass wouldn’t be in this game,” Shire’s Harrington said. “Fix the patent office, this goes away. Bass brilliantly figured out that once it’s filed there’s a good chance the petition will be instituted and then the patent may fall.”
Harrington said Shire’s stock price dropped 30 percent when the CAD’s petitions were instituted. “You may notice that Bass hasn’t filed any petitions recently. He has indicated there are less time-consuming ways to make money,” Harrington said.
Harrington offered more criticism of the IPR process.
When Conlon said the PTAB has issued only eight precedential opinions, which are the only decisions binding on future IPR cases, Harrington said: “This makes it easier for them to do anything they want.”
He disagreed with the PTAB’s statements that the patents it has invalidated have been weak ones. “I would argue that they are the strongest patents, the ones we have worked on the most, the ones that are being commercially challenged.”
He gave some advice to those whose products are the subject of an IPR petition: “Get experts on board fast. It’s impossible to win these things without an expert.”
Harrington said an IPR proceeding is more like an appellate argument than it is a litigation. “You’ve got to pick the right counsel for that, and it might not be the same person as your litigation counsel. And get your in-house patent counsel involved from the beginning.”
Harrington concluded, “The IPR process is what it is. We’ve used it against other companies. If a petition against our patent is not instituted, we view it as a win just like they do if it’s instituted. If it’s filed and not instituted, analysts think the patent becomes stronger.”
To contact the reporter on this story: John T. Aquino in Washington at email@example.com
To contact the editor responsible for this story: Randy Kubetin at RKubetin@bna.com
Copyright © 2016 The Bureau of National Affairs, Inc. All Rights Reserved.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to firstname.lastname@example.org.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to email@example.com.
Put me on standing order
Notify me when new releases are available (no standing order will be created)